Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRMA-1001 phase 1/2 study in adults with chronic hepatitis B
2025-523619-12-00Phase 2Completed
- Sponsor
- nChroma Bio
- Start
- May 2026
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of CRMA-1001 in Chronic Hepatitis B (CHB), sponsored by nChroma Bio. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started May 2026; status: completed.
02
Drugs
CRMA-1001
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2025-523619-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523619-12-00.